ClinicalTrials.gov
ClinicalTrials.gov Menu

Neurofeedback as a Treatment Tool for Depression (NFD)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01544205
Recruitment Status : Completed
First Posted : March 5, 2012
Last Update Posted : December 15, 2016
Sponsor:
Collaborators:
Medical Research Council
National Institute for Social Care and Health Research
Information provided by (Responsible Party):
David Linden, Cardiff University

Brief Summary:
The purpose of the study is to investigate whether neurofeedback delivered via functional magnetic resonance imaging signals can be used to train depressed patients to self-regulate emotion networks and whether this improves clinical symptoms.

Condition or disease Intervention/treatment Phase
Unipolar Depression Other: fMRI-based neurofeedback Not Applicable

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 43 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Outcomes Assessor)
Primary Purpose: Treatment
Official Title: fMRI Based Neurofeedback as a Treatment Method for Depression
Study Start Date : March 2012
Actual Primary Completion Date : September 2014
Actual Study Completion Date : September 2014

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Arm Intervention/treatment
Experimental: Emotion network up-regulation
Participants use fMRI-based neurofeedback to train the upregulation of brain areas that respond to positive affective pictures (as identified during a functional localiser scan).
Other: fMRI-based neurofeedback
5 sessions lasting one hour each
Active Comparator: Place processing network up-regulation
Participants use fMRI-based neurofeedback to train the upregulation of brain areas that respond to place and house pictures (as identified during a functional localiser scan).
Other: fMRI-based neurofeedback
5 sessions lasting one hour each



Primary Outcome Measures :
  1. Change from Baseline in Hamilton Depression Rating Scale (HDRS) score at the end of intervention (after 5th session) [ Time Frame: Before start trial (baseline), after intervention (appr. 2 months) ]

Secondary Outcome Measures :
  1. Change from Baseline in Hamilton Depression Rating Scale (HDRS) score at follow-up [ Time Frame: Baseline, 3-month follow-up ]
  2. Change from Baseline in Hospital Anxiety and Depression Scale (HADS) anxiety score at the end of intervention (after 5th session) [ Time Frame: Baseline, end of intervention (appr. 2 months) ]
  3. Change from Baseline in Hospital Anxiety and Depression Scale (HADS) anxiety score at follow-up [ Time Frame: Baseline, 3-month follow-up ]
  4. Change from Baseline in Hospital Anxiety and Depression Scale (HADS) depression score at the end of intervention (after 5th session) [ Time Frame: Baseline, end of intervention (appr. 2 months) ]
  5. Change from Baseline in Hospital Anxiety and Depression Scale (HADS) depression score at follow-up [ Time Frame: Baseline, 3-month follow-up ]
  6. Change from Baseline in the Quality of Life Scale (QOLS) at the end of intervention (after 5th session) [ Time Frame: Baseline, end of intervention (appr. 2 months) ]
  7. Change from Baseline in the Quality of Life Scale (QOLS) at follow-up [ Time Frame: Baseline, 3-month follow-up ]
  8. Change from Baseline in the European Quality of Life-5 dimensions scale (EQ-5D) at the end of intervention (after 5th session) [ Time Frame: Baseline, end of intervention (appr. 2 months) ]
  9. Change from Baseline in the European Quality of Life-5 dimensions scale (EQ-5D) at follow-up [ Time Frame: Baseline, 3-month follow-up ]

Other Outcome Measures:
  1. Change from Baseline in the Self-efficacy-scale (general subscale: GSE) at the end of intervention (after 5th session) [ Time Frame: Baseline, end of intervention (appr. 2 months) ]
  2. Change from Baseline in the Self-efficacy-scale (general subscale: GSE) at follow-up [ Time Frame: Baseline, 3-month follow-up ]
  3. Change from Baseline in the Self-efficacy-scale (social subscale: SSE) at the end of intervention (after 5th session) [ Time Frame: Baseline, end of intervention (appr. 2 months) ]
  4. Change from Baseline in the Self-efficacy-scale (social subscale: SSE) at follow-up [ Time Frame: Baseline, 3-month follow-up ]
  5. Change from Baseline in the Thought control questionnaire (TCQ) at the end of intervention (after 5th session) [ Time Frame: Baseline, end of intervention (appr. 2 months) ]
  6. Change from Baseline in the Thought control questionnaire (TCQ) at follow-up [ Time Frame: Baseline, 3-month follow-up ]
  7. Change from Baseline in the Thought control ability questionnaire (TCAQ) at the end of intervention (after 5th session) [ Time Frame: Baseline, end of intervention (appr. 2 months) ]
  8. Change from Baseline in the Thought control ability questionnaire (TCAQ) at follow-up [ Time Frame: Baseline, 3-month follow-up ]
  9. Change from Baseline in the Behavioural inhibition system and behavioural activation system (BIS/BAS), BAS scale, at the end of intervention (after 5th session) [ Time Frame: Baseline, end of intervention (appr. 2 months) ]
  10. Change from Baseline in the Behavioural inhibition system and behavioural activation system (BIS/BAS), BAS scale, at follow-up [ Time Frame: Baseline, 3-month follow-up ]
  11. Change from Baseline in the Behavioural inhibition system and behavioural activation system (BIS/BAS), BIS scale, at the end of intervention (after 5th session) [ Time Frame: Baseline, end of intervention (appr. 2 months) ]
  12. Change from Baseline in the Behavioural inhibition system and behavioural activation system (BIS/BAS), BIS scale, at follow-up [ Time Frame: Baseline, 3-months follow-up ]
  13. Change from Baseline in health service resource use as measured with a Resource Use Questionnaire [ Time Frame: Baseline, 3-months follow-up ]
  14. Change from before to after scan in the Profile of Mood States (POMS) [ Time Frame: Before and after each scanning session (appr. 2 months: session 1: week 1; session 2: week 2; session 3: week 3; session 4: week 4; session 5: week 8) ]
    Measure to address any imminent changes in mood state.

  15. Relation between upregulation ability of target areas (as obtained by functional MRI analysis) and perceived self control [ Time Frame: Integrating imaging and psychometric data across the intervention period (appr. 2 months) ]
    Analysis of the relationship between scores on the self-efficacy scales, thought control questionnaire (TCQ), thought control ability questionnaire (TCAQ) and the behavioural inhibition system and behavioural activation system (BIS/BAS) scales and fMRI data.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • major depressive disorder (MDD) diagnosis
  • stable antidepressant dose medication

Exclusion Criteria:

  • Other physical or psychiatric disorders
  • Current substance abuse
  • Current psychotherapy or other specific intervention
  • Exclusion criteria applicable to MRI

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01544205


Locations
United Kingdom
CUBRIC
Cardiff, Wales, United Kingdom, CF103AT
School of Medicine, Cardiff University
Cardiff, Wales, United Kingdom, CF14 4XN
Sponsors and Collaborators
Cardiff University
Medical Research Council
National Institute for Social Care and Health Research
Investigators
Principal Investigator: David E Linden, MD Cardiff University

Publications:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: David Linden, Professor of Translational Neuroscience, Cardiff University
ClinicalTrials.gov Identifier: NCT01544205     History of Changes
Other Study ID Numbers: SPON927-11
G 1100629 ( Other Grant/Funding Number: MRC )
HS/10/25 ( Other Grant/Funding Number: NISCHR )
11/WA/0106 ( Other Identifier: NHS Research Ethics Committee )
First Posted: March 5, 2012    Key Record Dates
Last Update Posted: December 15, 2016
Last Verified: December 2016

Additional relevant MeSH terms:
Depression
Depressive Disorder
Behavioral Symptoms
Mood Disorders
Mental Disorders